Experimental models of membranous nephropathy
نویسندگان
چکیده
منابع مشابه
Membranous Nephropathy
A forty-three year old female applied for a $200,000 ten year decreasing term policy. She admitted a history of "kidney disorder" on the application. She was not being treated or having any symptoms but stated that she was under observation. A routine paramed exam showed height 5’4", weight 140 lbs, and blood pressure 110/70. The BCP was normal. The HOS showed 210 mg/dl proteinuria. A reflex de...
متن کاملMembranous Nephropathy
Forty-one patients with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month course of cyclosporine (CsA; 4 to 5 mg/kg per day). Differential solute clearances were used to evaluate glomerular function before and after therapy. CsA lowered median proteinuria by 56%, from 7.3 to 3.2 g/24 h (P < 0.0001). Corresponding mean increments in serum albumin, imm...
متن کاملMembranous Nephropathy
Membranous nephropathy (MN), a very common cause of nephrotic syndrome, is a glomerulopathy defined histopathologically by the presence of immune complexes on the extracapillary side of the glomerular basement membrane (GBM). Idiopathic membranous nephropathy (IMN) is an antibody-mediated glomerular disease with no defined etiology, histologically characterized by uniform thickening of glomerul...
متن کاملAntigens in experimental models of membranous nephropathy: are they involved in human disease?
way. Hyperkalaemia, for instance, has a direct stimulaIntroduction tory e ect on distal tubule K+ secretion resulting from an increase in distal tubule flow rate and from direct The treatment of hypertension by diuretics is always stimulation of aldosterone secretion [10]. Most of these fraught with the complication of the induction of e ector mechanisms a ect the principal cells of the hypokal...
متن کاملManagement of membranous nephropathy.
The management of membranous nephropathy first requires the recognition of whether the disorder is primary (idiopathic) or secondary. Next, a familiarity with its natural history and knowledge of our current capacity to predict those patients with the worst outcome is reviewed. Treatment options of those at risk of progression with immunosuppressive drugs is then discussed along with the requir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Discovery Today: Disease Models
سال: 2010
ISSN: 1740-6757
DOI: 10.1016/j.ddmod.2010.11.001